Trends in Biotechnology

Cells are the fundamental unit of life. Yet there is no natural cell for which all its life-essential functions are understood. Here we demonstrate a complete cell cycle for a synthetic cell undergoing selection, with genome replication, growth, resource acquisition via feeding, and genetically encoded division. The cell is encoded via a 90kb genome that includes functions needed for resource uptake, transcription, translation, growth, genome replication, and division. The resulting synthetic cell is sufficiently encouraging to support routinization of synthetic cell engineering workflows, and will ultimately underlie diverse applications across all of biotechnology.

DNA assembly is a cornerstone of synthetic biology, enabling the construction of bespoke genetic systems for applications ranging from metabolic engineering to DNA nanotechnology. Conventional Gibson Assembly (GA), the most widely used method, relies on 5' exonucleolytic resection and elevated temperatures ([~]50 {degrees}C), which together prevent the retention of 5' modifications and restrict compatibility with temperature-sensitive functionalities. Here, we report a DNA assembly strategy, 3 exonuclease-mediated low-temperature DNA assembly (3LTDA), which generates complementary 5' overhangs while preserving 5' end integrity. This approach enables the efficient assembly of blunt-ended, 5'-functionalised DNA fragments into both linear and circular constructs at ambient temperature (21 {degrees}C), with some assembly observed at temperatures as low as 4{degrees}C. We systematically optimise reaction conditions and demonstrate that this method supports efficient plasmid re-circularisation and multi-fragment assembly, including the construction of a [~]12.5 kbp plasmid from multiple DNA components. Comparative analysis across several DNA substrates shows that, under their respective optimal conditions, this approach matches or exceeds GA performance, improving assembly efficiency by up to 12.8%. Sequence analysis confirms high fidelity with no detectable base-pairing errors across assembled junctions. Crucially, this method preserves chemically functionalised 5' termini, enabling downstream conjugation and biochemical functionality. Retention of azide and biotin modifications was verified through fluorescence imaging, bead-based co-localisation, and enzymatic activity in ELISA-based assays. This is in contrast to GA-assembled controls, which showed complete loss of functionality under comparable conditions. We further assembled 5 kbp dsDNA using 3LTDA from four independent segments, three with different fluorescence reporters, and the fourth containing a biotin group for microparticle conjugation, each on the 5 end. Under fluorescence illumination, bead-bound DNA with all three fluorescence markers were detected. Conventional GA assembled constructs, on the other hand, failed to retain the reporter groups and the fluorescent images did not show the presence of any fluorescent markers. In addition to enhanced performance, the method could also reduce reagent cost and eliminate the need for elevated temperatures, simplifying workflows and expanding the applicability of multi-functionalised DNA constructs. Collectively, this work establishes 3LTDA as a robust, low-temperature alternative to conventional GA, with advantages for applications requiring precise chemical modification, temperature-sensitive components, or deployment outside conventional laboratory environments.

The Modular Cloning (MoClo) and PhytoBrick standards have revolutionized plant synthetic biology by establishing a standardized, hierarchical assembly grammar. However, as the engineering of complex metabolic pathways, multi-trait stacks, and synthetic gene circuits expands, existing toolkits hit practical boundaries in assembly capacity and fixed grammars. To overcome these bottlenecks, we present MozClo, an expansion of the MoClo/PhytoBrick architecture. MozClo expands the standard Level 1 assembly framework to 10 positions using new L1 acceptors, end-linkers and dummy parts. We also identify and resolve a critical, sticky-end collision at L1 position 7 that has caused assembly failures during L2 cloning of large plasmids. To address commercial DNA synthesis length constraints and to lower cloning costs, we designed a universal 5-in-1 gene fragment multiplexing system. This architecture embeds up to five distinct parts flanked by orthogonal pairs of BpiI restriction sites into a single synthesized fragment, allowing them to sort independently into their respective L0 acceptor plasmids while maintaining complete modular flexibility of part types. Finally, we provide Level 2 cloning backbones with built in selection genes for common soybean transformation methods to facilitate downstream plant selection. Together, these advancements reduce DNA synthesis overhead and accelerate the construction of complex multigene payloads for plant biotechnology.

Compact tissue-specific promoters are highly desirable for gene therapy because viral vectors possess limited packaging capacity. However, existing promoter engineering strategies rely primarily on rational design or de novo sequence generation and lack efficient approaches for compressing long native promoters while preserving regulatory specificity. Although genome foundation models have substantially improved sequence-to-function prediction, they have not been effectively translated into computational platforms for promoter engineering. Here, we present VirEvo, a computational promoter engineering framework that integrates a virtual dual-luciferase assay (VirDLA), genome-foundation-model-guided genetic evolution, and an orthogonal Pan-Tissue Consistency Filter (PTCF). VirDLA introduces an internal-reference normalization strategy inspired by dual-luciferase reporter assays, enabling relative comparison of promoter activity across tissues without retraining AlphaGenome. Guided by these normalized activity scores, VirEvo iteratively optimizes promoter selectivity, off-target activity, and sequence length. Using the human p16INK4a promoter as a proof of concept, VirEvo evolved a compact synthetic promoter, SRP2M, of only 398 bp, representing an 85.9% reduction in sequence length. Experimental validation using dual-luciferase reporter assays in senescent IMR90 fibroblasts demonstrated that SRP2M retained 77% of wild-type senescence selectivity while reducing basal leakage to 52% of the wild-type level. Together, these results demonstrate the feasibility of genome-foundation-model-guided promoter engineering. VirEvo provides a generalizable framework for designing compact tissue-specific regulatory elements and extends the application of genome foundation models from functional prediction to synthetic regulatory engineering.

High-quality plasmid DNA purification at high throughput remains a significant bottleneck in molecular biology and bioengineering. Current methods frequently fail to deliver sufficient yields of pure, transfection-grade DNA required for genetic engineering applications in mammalian cells. Here, we present a Biofoundry-based automated pipeline using the CyBio FeliX robotic liquid handling platform to rapidly purify plasmid DNA with minimal manual intervention. The protocol leverages Solid Phase Reversible Immobilisation (SPRI)-based magnetic bead technology to ensure consistency, scalability, and DNA purity suitable for downstream viral particle production and mammalian cell transfection. The pipeline supports flexible processing of between 8 and 96 samples per run, making it adaptable across a wide range of experimental scales. The protocol is openly available via Earlham Institute GitHub repository, enabling broad adoption across the bioscientific community and contributing to the growing toolkit of reproducible, scalable engineering biology workflows. In this work, we employed an integrated robotic pipeline to process 528 pooled DNA plasmids and built a Lentiviral DNA plasmid library for lineage tracing, validated the library by sequencing, and demonstrated efficacy in downstream mammalian cell transfection experiments.

Carbonic anhydrases are among the fastest known biocatalysts, reversibly facilitating the hydration of CO2 to HCO3- at rates up to 107 s-1, which warrants their investigation for industrial carbon capture technologies. However, engineering carbonic anhydrases to maintain stability under harsh industrial process conditions remains a key challenge, and sequence-to-function datasets compatible with machine learning to inform forward engineering are lacking. Here, we developed a high-throughput platform that couples cell-free gene expression with a gaseous CO2 colorimetric assay to map the fitness landscapes of carbonic anhydrases. From 96 diverse natural homologs, we identified a robust variant from the Aquificota phylum and conducted an exhaustive mutational scan and functional assessment of this enzyme at 70C and 90C, covering >99% of all single-amino acid substitutions (totaling 4,365 mutations assayed in 39,285 reactions). This biochemical landscape was used to benchmark 22 zero-shot protein fitness models and identify critical mutations that improved enzyme stability at 90C by more than three-fold. We then used both zero-shot protein language models and supervised learning to filter 419 model-generated variants from a ProteinMPNN library of 100,000 sequences, leading to a best-in-class enzyme that retained activity after incubation at 95C. This work demonstrates that integrating cell-free enzyme engineering with machine learning enables opportunities for high-throughput experimental measurements to benchmark and improve protein language models, accelerate design loops, and expand functional exploration within protein families where experimental information is limited.

The rapid emergence of SARS-CoV-2 variants that evade neutralizing antibodies underscores the need for next-generation antiviral biologics that combine molecular precision with scalable, cost-effective manufacturing. Computationally designed miniproteins targeting the receptor-binding domain (RBD) of the spike protein offer a compelling alternative to monoclonal antibodies due to their small size, high thermal stability, and compatibility with microbial expression systems. Here we report the end-to-end development and cGMP production of IPD-52520, a de novo antiviral miniprotein, using an optimized E. coli platform. Two miniprotein candidates, a homotrimeric construct (Trimer is referred to as IPD-52520, 17 kDa) and a tandem fusion (Daisy is referred to as IPD-52521, 25 kDa), were evaluated in parallel through systematic optimization of strain selection, media composition, fed-batch fermentation, inclusion-body solubilization, refolding, and chromatographic purification. The Trimer was downselected as the lead molecule based on superior preclinical efficacy, favorable pharmacokinetic properties, and higher volumetric manufacturing yields. The optimized process delivers approximately 2 g/L of purified protein at greater than 90% purity. Scale-up from 5 L to 50 L under cGMP conditions demonstrated excellent batch-to-batch reproducibility across six independent batches, supporting nonclinical and Phase 1 clinical supply. Comprehensive biophysical characterization confirmed a well-folded, predominantly alpha-helical trimer (Tm = 73.4 {degrees}C; polydispersity = 1.005) with an intact primary structure and strong target-binding affinity (KD < 1 pM). Real-time stability studies indicate that the drug substance is stable at 2-8 {degrees}C for at least 12 months, with ongoing stability studies. These results demonstrate the feasibility of translating computationally designed antiviral miniproteins into manufacturable biologics and provide a platform applicable to rapid-response therapeutics against current and future pandemic threats.

The successful translation of rationally designed HIV-1 immunogens into effective vaccines requires manufacturing platforms that maintain structural conformity while meeting clinical-grade quality standards. We developed and scaled a robust, cGMP-compliant process for N332-GT5 gp140, a germline-targeting envelope trimer designed to initiate broadly neutralizing antibody responses, which is now undergoing first-in-human evaluation in HVTN144. Starting with a stable CHO cell line developed using Leap-In(R) transposon technology, we established a production clone exhibiting high-titer expression (>200 mg/L) and genetic stability through 60 population doublings. The manufacturing process scaled efficiently from Ambr(R) 250 miniature bioreactors to 200-L single-use systems, delivering consistent product quality across multiple cGMP batches. A streamlined three-step purification strategy--affinity capture, multimodal polishing, and viral clearance- yielded >99% trimeric purity with preserved quaternary structure and native-like antigenicity. Orthogonal LC-MS analyses confirmed site-specific glycan occupancy matching design specifications, while robust viral clearance exceeded 18-log and 11-log reductions for model retroviruses. Clinical material manufactured through this platform has been successfully administered in HVTN144. This work establishes a scalable, reproducible manufacturing paradigm for structurally complex HIV-1 envelope immunogens, advancing the field toward rational vaccine design based on germline-targeting principles.

Messenger RNA (mRNA)-based therapeutics have emerged as a new class of biological medicines, clearly exemplified by the global deployment of mRNA vaccines against the COVID-19 pandemic. Currently, therapeutic mRNA is primarily produced through in vitro transcription that suffers high production costs. Until now, intracellular manufacture of mRNA has been challenging due to the presence of ubiquitous RNases in vivo. Here, we have developed a new approach that protects eukaryotic mRNA from RNase degradation ensuring longevity and integrity of mRNA inside microbial cells. Through targeted strain and molecular engineering, our approach involves specially designed inserts in mRNA that facilitate formation of stabilized and protected protein-mRNA complexes. In addition to vastly improved stability, the protein-mRNA complexes enable convenient purification of mRNA from cell lysate with high purity using conventional chromatography. The work reported here promises a scalable, rapid, and low-cost approach to produce fully functional eukaryotic mRNA using well-known microbial systems.

Directed evolution consisting of iterative rounds of diversification, selection, and counter-selection, underlies modern protein and antibody engineering, yet small-molecule drug design still advances largely through high-throughput screening and medicinal-chemistry intuition. Transformer softmax attention is mathematically identical to the Boltzmann distribution that governs molecular binding at thermal equilibrium1, an isomorphism that prescribes a sequence-native Specificity Foundation Model (SFM)2. This framework was recently applied across seven molecular recognition domains3,4 and scaled into the drug-target SFM (dtSFM), the first to pair a full-scale encoder with a generative decoder5. Whether such a model can be driven, iteratively and under selection, to optimize leads rather than sample them once has not been shown. Here we present GenLoop, a closed generative drug design loop that turns single-pass generation into directed evolution of chemistry. dtSFM generates target-conditioned molecules and reranks them by their thermodynamic compatibility score. An orthogonal structural verifier, AlphaFold 3, is used that shares no architecture or training data with dtSFM. Cheminformatics filters enforce developability, and generative evolution is performed on the structurally verified candidates, selecting for predicted binders and counter-selecting against off-target chemistry. Applied across twelve drug targets spanning pharmacologically distinct mechanism classes, GenLoop produced AlphaFold 3-verified designs that reached the structural confidence of the approved drug for five of the twelve targets, with the best designs at interface iPTM 0.93-0.98 and PAE 0.8-2.0 [A], as well as resolving paralog selectivity across nine targets. Two full disease campaigns followed. For the cystic-fibrosis transmembrane conductance regulator, GenLoop designed nine developability-filtered and structurally novel lead candidates (iPTM up to 0.93, interface PAE 2.3 [A]) targeting all three orthogonal sites of the approved drug Trikafta. For the GLP-1 receptor family, dtSFM engineered tunable single-, dual-, and triple-receptor incretin designs, yielding 23 central-pocket candidates that are structurally novel at median iPTM 0.89 and interface PAE 1.95 [A]. GenLoop with dtSFM brings directed evolution to small molecules through computational-thermodynamic selection; wet-lab validation is the immediate next step.

Cannabinoids comprise a diverse class of bioactive natural products with important therapeutic potential, but efficient microbial production remains limited by pathway bottlenecks and challenges in engineering key biosynthetic enzymes. Here, we develop a machine learning-guided approach to engineer olivetolic acid cyclase (OAC), a critical control point in cannabinoid biosynthesis that governs both pathway flux and product selectivity. We first generated sequence-function data from 152 CsOAC variants spanning homolog screening, recombination, and mutagenesis libraries. Using these measurements, we trained multi-task models to predict pathway-level production of olivetolic acid (OA), divarinic acid (DVA), and competing byproducts, together with a variational autoencoder that captured evolutionary constraints across the broader enzyme family. Across three rounds of iterative design and testing, this approach identified CsOAC variants that substantially increased production and selectivity of both OA and DVA. When introduced into engineered Yarrowia lipolytica strains, these variants enabled production of tetrahydrocannabinolic acid (THCA) and the minor cannabinoid tetrahydrocannabivarinic acid (THCVA) at titers exceeding previous yeast systems. Analysis of top-performing variants revealed mutations influencing substrate selectivity and catalytic performance, providing insight into the determinants of CsOAC function. More broadly, this work demonstrates how machine learning-guided enzyme engineering can improve pathway performance and expand access to major and minor cannabinoids through microbial biosynthesis.

Here we introduce OpenEvo, a fully open-source, low-cost turbidostat platform for automated continuous culture and directed evolution experiments. Existing tools are expensive, complex, or lack open-source hardware; OpenEvo addresses this gap. OpenEvo is a complete, fully automated evolution platform with detailed, illustrated construction instructions for beginners, open-source software and firmware, and a single device priced around $300. An optional PC-based version offers enhanced functionality, including remote access, programmable evolution cycles, programmable LED stimulation, and a data visualization tool. OpenEvo can cycle through three types of media for positive, negative, and neutral selection conditions, supporting a wide range of experimental designs. We validate the use of OpenEvo by evolving H. volcanii to grow from 15% to 12% salt over ~150 cycles, ~1,000 hours. Evolved cells grew 36% faster than wild-type at 12% salt. Whole-genome sequencing of adapted cells found SNPs and large deletions. We also demonstrate positive and negative selection using the OpenEvo LEDs to drive optogenetics via a Phytochrome B-based optogenetic tool, with light as the selection stimulus during over 4000 hours of growth. OpenEvo lowers the technical and cost barriers for continuous evolution experiments, serves as a teaching tool, and is designed to grow an open community of users who share modifications.

Chimeric antigen receptor (CAR)-T cell therapies have transformed the treatment of various tumor types by redirecting and activating T cells against tumor cells. However, CAR-T cell manufacturing approaches remain challenging and limit their widespread use in clinical settings. In vivo CAR-T therapy bypasses ex vivo cell manufacturing and patient preconditioning limitations; however, it faces a significant safety concern as CAR proteins on viral packaging cells are incorporated into budding virions, leading to off-target transduction of tumor cells. Here, we address this risk by developing the CAR-Less ER-Anchor Vector (CLEAN-V) system. By exploiting endoplasmic reticulum (ER) retention, CLEAN-V prevents the CAR protein from trafficking to the cell surface during viral packaging, thereby blocking its incorporation into the viral envelope. CLEAN-V particles exhibit near-complete loss of CAR-mediated tumor cell transduction. Furthermore, CLEAN-V integrates seamlessly into existing third-generation LVV workflows in four- or five-plasmid formats and generates CAR-T cells with preserved phenotypic and functional integrity. These results establish CLEAN-V as a robust platform for developing safe, targeted lentiviral vectors for in vivo CAR-T therapy.

Multidrug-resistant pathogens pose a major threat to One Health. Within the past decade, CRISPR-Cas systems have been explored as sequence-specific antimicrobials. While chromosomal injury has been considered the primary mechanism underlying pathogen killing by CRISPR-Cas antimicrobials, the synergistic role of gene disruption together with chromosomal injuries remains poorly understood. In this study, we characterized a new class of CRISPR-Cas antimicrobials that simultaneously cotarget essential and defensive genes to enhance potency against the clinically relevant pathogen Staphylococcus aureus. High-throughput CRISPR screening identified top-performing guide RNAs for twenty functionally diverse essential and defensive genes across the S. aureus genome. CRISPR-Cas antimicrobials were modularly formulated to target single or multiple gene loci and packaged in phage-like particles for specific delivery. By engineering an S. aureus production host with a chromosomally integrated anti-CRISPR protein, we demonstrated efficient production of CRISPR-Cas antimicrobials targeting any S. aureus chromosomal locus without self-targeting. Characterization of CRISPR-Cas antimicrobials with single guide RNA designs revealed that potency varied according to targeted gene function, achieving up to a 4-log10 reduction in viability and outperforming traditional antibiotics. Multiplexed configurations were consistently more effective than single-targeting designs, with the top-performing design demonstrating a 4.7-log10 reduction in viability. Cotargeting essential and defensive genes revealed synergies that led to improved lethality and attenuated resistance, with enhanced activity in biofilms compared to traditional antibiotics. Genes involved in signaling and stress responses were important defensive targets for developing cotargeting CRISPR-Cas antimicrobials. Overall, this study establishes design principles for synergistic CRISPR-Cas antimicrobials applicable to next-generation precision antimicrobial development. SIGNIFICANCEThe ability to effectively combat multidrug-resistant pathogens is of primary importance to One Health. This study develops a generalizable design principle for formulating potent CRISPR-Cas antimicrobials that exploit synergistic cotargeting strategies for enhanced pathogen killing. In addition to chromosomal injuries, we found that disruption of gene function plays a crucial role in determining the lethality of CRISPR-Cas antimicrobials, providing a generalizable framework for effective CRISPR-Cas antimicrobial design. The development of a CRISPR-Cas antimicrobial production host with stable, chromosomally integrated anti-CRISPR genes greatly expands the modularity, adaptability, and efficiency of formulating CRISPR-Cas antimicrobials and enables deeper insights into the molecular mechanisms involved in eliminating multidrug-resistant pathogens.

Messenger RNA (mRNA) is canonically composed of ribonucleotides, with sporadic incorporation of deoxyribonucleotides into natural RNA transcripts being traditionally regarded as a rare, deleterious error arising from transcriptional infidelity. Here, we challenge this paradigm by demonstrating controlled partial substitution of ribonucleotides with deoxyribonucleotides during in vitro transcription (IVT) generates intact, stable and fully translationally competent IVT-mRNA. Unexpectedly, chimeric DNA-RNA backbone modification exhibits markedly enhanced IVT-mRNA translation several fold across multiple cell types and in vivo via diverse dosing routes relative to their ribonucleotide-based counterparts. 25% substitution of cytidine triphosphate with deoxycytidine triphosphate achieved best-performing translational output, surpassing the current gold-standard N1-methylpseudouridine (m1{Psi})-modified IVT-mRNA in a B16-OVA tumor vaccination model. These findings identify nucleotide class composition as a previously unrecognized parameter governing IVT-mRNA function and establish hybrid ribonucleotide-deoxyribonucleotide backbone engineering as a versatile strategy to expand the chemical space for next-generation mRNA therapeutics.

Adeno-associated virus (AAV)-based gene therapy has made steady progress towards efficient delivery to numerous target cell populations, yet the virus's 5 kb packaging limit remains a challenge for effective and in some cases cell-selective cargo expression. Here, we introduce Expression-Linked Promoter Selection (ELiPS), a high-throughput platform for generating and functionally screening >106 engineered, short promoter variants using an AAV expression platform. ELiPS relies on a Golden Gate cloning method to build random oligomers of selected transcription factor binding sites (TFBSs) upstream of a minimal promoter, GFP, and a unique 3' barcode. As a proof of concept, to engineer short (~250 bp), synthetic, ubiquitous promoters, we applied ELiPS to build two libraries composed of TFBSs for ubiquitously expressed transcription factors (TFs) and screened them via AAV-mediated transduction in vitro. This strategy identified promoters with expression surpassing human cytomegalovirus (CMV) and CAG in vitro, and one variant was capable of driving therapeutic expression of B-domain-deleted Factor VIII (BDDFVIII) in vivo at levels comparable to a liver-specific promoter benchmark. ELiPS thus establishes a scalable framework for promoter discovery, enabling the design of compact, ubiquitous or cell-selective expression cassettes that enable further precision and efficacy in AAV-based gene therapies.

Intestinal organoids are powerful in vitro models, but their use in large-scale analyses remains constrained by the low throughput, labor-intensive handling, and high reagent consumption of conventional Matrigel dome culture. Here, we present Organoid-in-Bead (OrB), a vortex-based compartmentalization workflow that partitions organoid fragments into thousands of discrete Matrigel microbeads, enabling scalable, high-density culture from a single batch preparation. OrB maintains dome-comparable organoid growth and epithelial polarity, supports passaging-based culture expansion, yields more than 5,000 organoids in the final 10 cm dish format, and reduces Matrigel and medium consumption by approximately 70% on a per-organoid basis. OrB therefore provides a practical and scalable upstream workflow for generating screening-scale intestinal organoids. HighlightsO_LIOrB generates Matrigel microcompartments by vortexing without microfluidics C_LIO_LIOrB enables scalable, high-density intestinal organoid culture in one batch C_LIO_LIOrB maintains dome-comparable growth and epithelial polarity and supports passaging C_LIO_LIOrB yields >5,000 organoids per batch with [~]70% less Matrigel/medium per organoid C_LI

Methanogenic archaea, such as Methanothermobacter marburgensis, represent a powerful biological platform for carbon capture and valorization, directly converting carbon dioxide (CO2) and molecular hydrogen (H2) into proteinogenic amino acids (AAs). In this study, we present a controlled and scalable strategy for tailoring AA production (biosynthesis and secretion) in continuous gas fermentation. By applying various Design of Experiments (DOE) techniques, we systematically identified and optimized key process parameters governing AA biosynthesis and shaping a targeted AA secretion profile. A hybrid modeling framework combining experimental data with scale-independent parameters derived from computational fluid dynamics (CFD) enabled robust performance prediction across bioreactor scales. This model-driven approach successfully translated the process from 120 mL glass bottles via 2 L to 150 L reactors, corresponding to a reaction-volume scale-up factor of 2000. These findings set the foundation for a robust and predictive platform for sustainable AA production, positioning archaea as a high-potential alternative in industrial biotechnology.

RNA-based sensors offer powerful and programmable control of gene expression, yet our understanding of the structural principles that govern their potential design space remains incomplete. Here, we challenged a community of designers to generate novel riboregulators capable of activating translation in response to specific RNA targets. Participants submitted diverse sequence architectures, which were synthesized and evaluated in a cell-free transcription-translation system. Across 100 designs, community-generated riboregulators displayed wide variability in activation dynamics, fold change, and structural features, outperforming some canonical toehold-switch designs and achieving up to 80-fold activation. Structural ensemble analyses identified accessibility patterns near the ribosome binding site that distinguish high- from low-performing regulators, highlighting the central role of RBS sequestration and release in modulating expression. Together, we demonstrate community-driven design can expand the accessible structural space of riboregulators and uncover mechanistic features governing translational activation. Our findings establish quantitative links between RNA folding energetics and gene expression output, providing design principles for next-generation programmable RNA sensors.

Efficient, cell type-selective delivery of genetic payloads remains a central challenge in the development of gene and cell therapies. Lipid nanoparticles (LNPs) offer a versatile delivery platform, but their optimization is hindered by reliance on brute-force screening methods that are laborious, resource-intensive, and focus on single targets. Here, we present FALCON (Framework for Active Learning-driven Compositional Optimization of Nanoparticles), a closed-loop pipeline that leverages iterative screening, surrogate modeling, and multi-objective optimization to accelerate LNP compositional design. In B cell-targeted validation experiments, FALCON-optimized LNPs achieved a 1.8-fold increase in splenic B cell transfection in vivo compared with reference compositions. When optimized for selectivity, FALCON LNPs displayed an 84-fold improvement in selective transfection of splenic B cells over off-target liver populations and enabled spleen-tropic behavior across factorial panels of varying ionizable and helper lipid chemistries. In vaccine studies, these LNPs induced higher IgG2c antibody titers and a more Th1-biased immune profile. FALCON was also deployed to optimize LNPs for myeloid cell-selective delivery, achieving enhanced in vivo selectivity following systemic administration both across and within spleen and liver compartments. Our results establish FALCON as a useful tool for data-driven design of LNP compositions for precision gene delivery.